Sai Life Sciences Limited announced its unaudited financial results for the quarter and nine months ended 31 December 2025, showcasing strong operational performance across both standalone and consolidated metrics. The Hyderabad-based contract research, development and manufacturing services company reported significant year-on-year growth in revenue and profitability, with notable improvement in EBITDA margins despite facing exceptional charges during the quarter.

EBITDA Performance Demonstrates Operational Excellence

The company delivered exceptional EBITDA performance in Q3FY26, with EBITDA reaching Rs. 1.9 billion compared to Rs. 1.2 billion in the corresponding quarter last year. This represents substantial growth in operational efficiency, with EBITDA margin expanding significantly to 33.76% from 27.23% year-on-year, highlighting the company's ability to optimize costs while scaling operations.

Consolidated Performance Shows Strong Growth

On a consolidated basis, which includes subsidiaries in the USA, Germany, and India, revenue from operations reached Rs. 5,564.64 million in Q3FY26, up 26.53% from Rs. 4,397.78 million in Q3FY25. Consolidated net profit grew substantially to Rs. 1,003.75 million from Rs. 538.51 million, marking an 86.41% increase year-on-year.

Standalone Results Demonstrate Robust Performance

The company's standalone revenue from operations reached Rs. 5,491.79 million in Q3FY26, representing a robust 28.14% increase compared to Rs. 4,286.02 million in Q3FY25. Sequential growth was also positive, with revenue rising 4.27% from Rs. 5,266.69 million in Q2FY26.

Exceptional Profit Growth Despite Regulatory Impact

Standalone net profit for Q3FY26 surged 91.22% year-on-year to Rs. 976.30 million from Rs. 510.57 million in the corresponding quarter last year. This impressive growth was achieved despite exceptional charges of Rs. 82.93 million related to the implementation of new Labour Codes.

Nine-Month Performance Reflects Sustained Growth

For the nine months ended 31 December 2025, Sai Life Sciences demonstrated consistent performance with revenue from operations reaching Rs. 15,588.86 million, up 45.01% from Rs. 10,750.42 million in 9MFY25. Net profit for the nine-month period increased substantially to Rs. 2,389.49 million compared to Rs. 835.27 million in the previous year, representing growth of 186.05%.

Sai Life Sciences has announced a strategic partnership with Mabtech to strengthen immunology research capabilities and expand service offerings in the biotechnology sector. This collaboration marks a significant step in enhancing the company's research infrastructure and global presence.

Strategic Partnership Details

The partnership between Sai Life Sciences and Mabtech focuses on boosting immunology research through combined expertise and resources. The collaboration aims to leverage both companies' strengths to deliver enhanced research capabilities and advanced scientific solutions.

Boston Laboratory Establishment

As part of this strategic initiative, Sai Life Sciences has opened a new laboratory facility in Boston, which will serve as the US hub for the Eyra platform. This expansion represents the company's commitment to strengthening its presence in the American market and providing localized services to clients.

Enhanced Service Capabilities

The partnership will enable both companies to jointly provide advanced immunology assay services. This collaboration combines Sai Life Sciences' research capabilities with Mabtech's specialized expertise, creating a comprehensive service offering for clients in the immunology research sector.

The establishment of the Boston facility and the strategic partnership with Mabtech demonstrates Sai Life Sciences' focus on expanding its global footprint and enhancing its research and development capabilities in specialized areas of biotechnology.